August 2023

Quanta Round

Quanta™ Announces Enrollment Completion in Home Run Study.

Latest News, Quanta /

Beverly, Massachusetts, U.S.A. 17 August 2023.  Seroba’s portfolio company, Quanta Dialysis Technologies®, today announced that it has completed enrollment of its Home Run study for at-home hemodialysis.  The Home Run study is a prospective, multi-center, open-label trial to assess the efficacy and safety of the Quanta Dialysis System for home hemodialysis.  Results are expected to […]

Quanta™ Announces Enrollment Completion in Home Run Study. Read More »

Image 2994

Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer.

ComplementTherapeutics, Latest News /

Munich, Germany. 2 August 2023.  Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, has announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer.  Dr. Zamiri brings with her extensive experience in biopharmaceutical and small molecule drug discovery and development, drug and device safety, pharmacovigilance, and

Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer. Read More »

Quanta Round

Quanta™ Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies.

Latest News, Quanta /

Beverly, Mass., USA. 3 August, 2023.  Quanta Dialysis System becomes first-in-class to perform three standard-of-care dialysis modalities in one device. Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication of the Quanta Dialysis

Quanta™ Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top